EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Dose Optimization of rhIL ‐7‐ hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor‐Mediated Recycling‐Based and Target‐Mediated Drug Disposition Pharmacokinetic Model

Hye Seon Jeon iD, Sang Won Lee, Woojin Jung iD, Heeyoon Jung, Donghoon Choi, Mi-Sun Byun, Hwi-Yeol Yun iD, Soyoung Lee iD, Anhye Kim iD, Jung-Woo Chae iD, Howard Lee iD

Clinical and Translational Science · 2025-05 · 18 (5)

DOI: 10.1111/cts.70252 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 21.05.2025. Verfasst von Hye Seon Jeon und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Lymphopenia, Receptors, Fc, Interleukin-7, Recombinant Fusion Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recombinant human interleukin‐7 hybrid Fc (rhIL‐7‐hyFc) is a homodimer of rhIL‐7 fused to a hyFc. Exogenous IL‐7 promotes T cell proliferation and increases lymphocyte count, making it a potential treatment option for lymphopenia and cancer. To improve therapeutic efficacy, rhIL‐7‐hyFc was developed as a long‐acting IL‐7. This study aimed to create a pharmacokinetic model for rhIL‐7‐hyFc by incorporating neonatal Fc receptor (FcRn)‐mediated recycling and target‐mediated drug disposition (TMDD) of the IL‐7 receptor. Data were collected from a randomized, double‐blind, placebo‐controlled phase 1 trial involving 30 healthy volunteers who received single doses of rhIL‐7‐hyFc. Volunteers received 20 or 60 mg/kg subcutaneously, 60 mg/kg intramuscularly (IM), or a placebo. Clinical data were provided by Genexine Inc. (Seoul, Republic of Korea). A TMDD‐FcRn–mediated recycling pharmacokinetic model was developed using NONMEM 7.5 software, assisted by PsN 5.3.1 software. A quasi‐steady‐state approximation was used to describe drug‐receptor and drug‐FcRn interactions. The model evaluation included goodness of fit, visual predictive checks, and bootstrap analysis. Based on the pharmacokinetic parameters of the final model, a simulation was conducted to select the dosage regimen, ensuring a probability of at least 0.8 for meeting both safety and efficacy criteria. The model successfully described the pharmacokinetic profiles of 24 patients administered rhIL‐7‐hyFc. Based on the simulation results, 670–800 μg/kg every 3 weeks, 1010–1530 μg/kg every 6 weeks, and 1510–2190 μg/kg every 9 weeks IM were proposed. These results may help further understand rhIL‐7‐hyFc characteristics and, moreover, provide guidance for selecting the appropriate dosing regimen in future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphopeniaReceptors, FcInterleukin-7Recombinant Fusion ProteinsHumansDouble-Blind MethodAdultMaleFemaleModels, BiologicalYoung AdultDose-Response Relationship, DrugHealthy VolunteersMiddle AgedHistocompatibility Antigens Class I

Stichwörter der Autor:innen

lymphopeniaoptimal dosing for clinical trialsrhIL‐7‐hyFcsemi‐mechanistic model

Substanzen

Receptors, FcFc receptor, neonatalInterleukin-7Recombinant Fusion ProteinsIL7 protein, humanHistocompatibility Antigens Class I

Autor:innen und Institutionen

  • College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
  • Department of Pharmacology, Hanyang University, College of Medicine, Seoul, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, Hanyang University Seoul Hospital, Seoul, Republic of Korea.
  • Population Health Sciences Program, Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Research Institute of NeoImmuneTech, Inc., Pohang, Republic of Korea.
  • Clinical Development Department, Genexine, Inc., Seoul, Republic of Korea.

ORCID-Profile: Hye Seon Jeon, Woojin Jung, Hwi-Yeol Yun, Soyoung Lee, Anhye Kim, Jung-Woo Chae, Howard Lee

Zitieren

APA

Jeon, H. S., Lee, S. W., Jung, W., Jung, H., Choi, D., Byun, M. S., Yun, H. Y., Lee, S., Kim, A., Chae, J. W., & Lee, H. (2025). Dose Optimization of rhIL ‐7‐ hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor‐Mediated Recycling‐Based and Target‐Mediated Drug Disposition Pharmacokinetic Model. Clinical and Translational Science, 18(5). https://doi.org/10.1111/cts.70252

Vancouver

Jeon HS, Lee SW, Jung W, Jung H, Choi D, Byun MS, et al. Dose Optimization of rhIL ‐7‐ hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor‐Mediated Recycling‐Based and Target‐Mediated Drug Disposition Pharmacokinetic Model. Clinical and Translational Science. 2025;18(5). doi:10.1111/cts.70252

BibTeX
@article{Jeon2025,
  author = {Jeon, Hye Seon and Lee, Sang Won and Jung, Woojin and Jung, Heeyoon and Choi, Donghoon and Byun, Mi-Sun and Yun, Hwi-Yeol and Lee, Soyoung and Kim, Anhye and Chae, Jung-Woo and Lee, Howard},
  title = {Dose Optimization of rhIL ‐7‐ hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor‐Mediated Recycling‐Based and Target‐Mediated Drug Disposition Pharmacokinetic Model},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {5},
  doi = {10.1111/cts.70252}
}
Kostenlos starten →